Biotech Upgrades: FATE, IMCR, IMRX Get Bullish Analyst Calls

Analysts upgrade Fate Therapeutics to Buy and initiate bullish coverage on Immunocore and Immuneering, citing promising drug trials and strong revenue potential in lupus and cancer treatments.